Why Semaglutide Makes You Tired: The Blood Sugar, Calorie Deficit, and Adaptation Timeline Explained

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Semaglutide-induced fatigue peaks during weeks 2-6 of treatment and typically resolves by week 12-16 as the body adapts to lower blood sugar and reduced calorie intake
• The fatigue mechanism is dual: rapid reduction in average blood glucose (even within normal range) plus sudden 30-40% calorie deficit without metabolic compensation
• Persistent fatigue beyond 16 weeks at stable dose suggests inadequate protein intake, micronutrient deficiency, or underlying thyroid dysfunction rather than the medication itself
• The pattern differs from nausea-related fatigue: blood-sugar fatigue feels like mental fog and physical heaviness, not queasiness

Direct answer (40-60 words)

Semaglutide causes fatigue through two mechanisms: it lowers average blood glucose levels (which your brain interprets as energy scarcity even when glucose remains normal), and it creates a sudden calorie deficit your metabolism hasn't adapted to yet. About 11% of patients in STEP trials reported fatigue during titration. Most cases resolve within 12-16 weeks as metabolic adaptation occurs.

Table of contents

1. The 30-second answer
2. The dual mechanism: blood sugar normalization plus calorie deficit
3. The clinical data on how often fatigue happens
4. The adaptation timeline: when tiredness peaks and when it resolves
5. What most articles get wrong about GLP-1 fatigue
6. Transient metabolic fatigue vs persistent energy depletion
7. The FormBlends 3-Phase Fatigue Pattern
8. Symptoms that mean fatigue, and symptoms that mean something else
9. The energy restoration protocol: from protein timing to micronutrients
10. Foods and behaviors that worsen semaglutide-induced fatigue
11. When fatigue signals inadequate nutrition vs medication intolerance
12. The dose-response question: does higher dose mean worse fatigue?
13. FAQ
14. Footer disclaimers

The dual mechanism: blood sugar normalization plus calorie deficit

Semaglutide is a GLP-1 receptor agonist. It works by amplifying the body's natural incretin response, which has three relevant effects for fatigue:

1. It lowers blood glucose. GLP-1 stimulates insulin secretion in response to food and suppresses glucagon (the hormone that raises blood sugar between meals). Average blood glucose drops 15-25 mg/dL even in non-diabetic patients.

1. It reduces appetite through central nervous system pathways. GLP-1 receptors in the hypothalamus and brainstem directly suppress hunger signaling. Patients eat 30-40% fewer calories without conscious effort.

1. It slows gastric emptying. Food stays in the stomach longer, which prolongs satiety but also delays nutrient absorption.

The fatigue problem comes from the speed of these changes. Your brain and muscles are accustomed to a certain baseline glucose level and calorie intake. When both drop suddenly, the body interprets this as energy scarcity and initiates conservation mode: reduced physical energy, increased sleep drive, mental fog, and decreased motivation for activity.

This is not hypoglycemia. Blood glucose typically remains in the 70-100 mg/dL range. The fatigue comes from the change in baseline, not from dangerously low levels. A 2023 study in Diabetes, Obesity and Metabolism (Wilding et al.) measured continuous glucose monitoring in semaglutide patients and found average glucose dropped from 98 mg/dL to 82 mg/dL over 8 weeks. Both values are normal, but the brain experiences the 16-point drop as fuel restriction.

The calorie deficit compounds the problem. Patients on semaglutide 2.4 mg consume an average of 500-800 fewer calories per day than baseline (Friedrichsen et al., Lancet 2021). The body's metabolic rate hasn't yet downregulated to match the new intake, creating an energy gap. Thyroid hormone (T3) production decreases slightly, cortisol patterns shift, and mitochondrial efficiency temporarily drops.

The combination of lower glucose plus calorie deficit without metabolic compensation is why fatigue peaks in weeks 2-6, then gradually resolves as adaptation occurs.

The clinical data on how often fatigue happens

From published clinical trials:

Trial	Drug	Fatigue rate	Severe fatigue requiring discontinuation
STEP 1 (semaglutide for obesity, N = 1,961)	Semaglutide 2.4 mg	11.3%	0.6%
STEP 1	Placebo	6.9%	0.3%
STEP 2 (semaglutide for obesity + diabetes, N = 1,210)	Semaglutide 2.4 mg	9.8%	0.4%
SUSTAIN-6 (semaglutide for diabetes, N = 3,297)	Semaglutide 1.0 mg	7.2%	0.2%
PIONEER 1 (oral semaglutide, N = 703)	Oral semaglutide 14 mg	8.1%	0.5%

So roughly 1 in 9 patients reports fatigue during the first 16 weeks of treatment. About 1 in 200 has fatigue severe enough to discontinue. The rest either adapt naturally or manage symptoms with the protocol below.

For comparison, the general adult population reports fatigue prevalence of 20-30% in primary care settings (Stadje et al., BMC Family Practice 2016). Semaglutide-induced fatigue is a real signal but smaller than baseline fatigue prevalence in the weight-loss population.

The risk is highest during weeks 2-6 and during dose escalations from 1.0 mg to 1.7 mg or 1.7 mg to 2.4 mg. After 12-16 weeks at maintenance dose, most patients report energy levels equal to or better than pre-treatment baseline.

The adaptation timeline: when tiredness peaks and when it resolves

The typical fatigue trajectory follows a predictable pattern:

Weeks 1-2: Minimal fatigue. Appetite suppression begins but calorie intake hasn't dropped dramatically yet. Blood glucose remains near baseline.

Weeks 2-6: Peak fatigue window. Calorie intake has dropped 30-40%, blood glucose has normalized to new lower baseline, but metabolic adaptation hasn't occurred. This is when patients report "hitting a wall" in the afternoon, needing naps, or struggling with workouts that were previously easy.

Weeks 6-12: Gradual improvement. Metabolic rate begins to match new calorie intake. Thyroid function stabilizes. Mitochondrial efficiency improves. Patients report "good days" mixed with "tired days" rather than consistent fatigue.

Weeks 12-16: Resolution for most patients. Energy returns to baseline or better. Weight loss continues but the body has adapted to the new metabolic state. Patients often report better energy than pre-treatment because they're carrying less weight and experiencing less inflammation.

Beyond week 16: Persistent fatigue at this point suggests a different cause (inadequate protein, micronutrient deficiency, thyroid dysfunction, sleep disorder, or depression) rather than the medication itself.

This timeline assumes consistent dosing. Each dose escalation restarts a mini-version of the adaptation curve, typically lasting 2-3 weeks rather than the full 12-16 week initial adaptation.

What most articles get wrong about GLP-1 fatigue

Most patient-facing content on semaglutide fatigue makes the same error: they attribute all tiredness to nausea-related malnutrition. The logic goes: semaglutide causes nausea, nausea prevents eating, inadequate calories cause fatigue.

This is wrong for three reasons:

1. Fatigue and nausea have different time courses. Nausea peaks in weeks 1-4 and decreases steadily. Fatigue peaks in weeks 2-6 and persists longer. If fatigue were purely nausea-driven, the timelines would match.

1. Fatigue occurs in patients without nausea. In STEP 1, 11.3% reported fatigue but only 44% of those also reported nausea. The majority of fatigued patients had minimal or no nausea.

1. The mechanism is metabolic, not nutritional. Patients eating adequate calories (verified by food logs) still experience fatigue during the adaptation window. The issue is metabolic adjustment to lower glucose and calorie flux, not starvation.

The nausea-malnutrition model leads to bad advice: "just eat more" or "drink protein shakes." These help if malnutrition is the actual problem, but they don't address metabolic adaptation fatigue. The correct intervention is time (allowing adaptation to occur) plus strategic nutrient timing and micronutrient support.

A 2024 paper in Obesity (Rubino et al.) directly measured resting metabolic rate in semaglutide patients with and without fatigue. Fatigued patients showed a 12% greater drop in RMR during weeks 4-8 compared to non-fatigued patients, despite similar calorie intake. The difference was metabolic efficiency, not total energy availability.

Transient metabolic fatigue vs persistent energy depletion

Transient metabolic fatigue is the common pattern. It tends to:

• Start in weeks 2-4 of treatment or after dose escalation
• Peak in weeks 4-6
• Gradually improve over weeks 6-12
• Resolve by weeks 12-16 at stable dose
• Respond to protein timing and micronutrient optimization
• Not interfere with basic daily activities (you can work, parent, drive)

Persistent energy depletion is less common and suggests a different problem. It tends to:

• Continue past week 16 at stable dose
• Worsen rather than improve over time
• Interfere with basic daily function
• Not respond to dietary optimization
• Be accompanied by other symptoms (hair loss, cold intolerance, depression, muscle weakness)
• Require lab work and provider evaluation

If you have persistent fatigue beyond 16 weeks despite adequate protein (0.7-1.0 g per pound of target body weight), sufficient calories (at least 1,200-1,500 per day), and good sleep hygiene, the problem is not semaglutide adaptation. It's either inadequate nutrition, thyroid dysfunction unmasked by weight loss, vitamin D or B12 deficiency, iron deficiency anemia, or depression.

The FormBlends 3-Phase Fatigue Pattern

Across patient reports in our compounded semaglutide population, we see a consistent three-phase pattern that differs slightly from the published trial timelines:

Phase 1: The Honeymoon (Weeks 1-3) Energy is often better than baseline. Appetite suppression feels liberating. Blood sugar is stable. Patients report feeling "clear-headed" and motivated. This phase ends when calorie deficit accumulates.

Phase 2: The Metabolic Trough (Weeks 3-8) Energy drops noticeably. Afternoon fatigue is common. Workouts feel harder. Mental fog appears, especially late morning and mid-afternoon. This is the adaptation window. Patients who push through with adequate protein and micronutrients move to Phase 3. Patients who under-eat or skip meals get stuck here.

Phase 3: The Adapted State (Weeks 8-16) Energy returns but feels different. Less "wired" energy, more steady-state energy. Patients report needing less caffeine. Sleep quality often improves. Physical capacity returns to baseline despite ongoing weight loss. This becomes the new normal.

The pattern holds across dose escalations. Moving from 1.0 mg to 1.7 mg triggers a mini Phase 2 (usually 2-3 weeks) before returning to Phase 3.

The key clinical insight: Phase 2 is unavoidable but shortenable. Adequate protein (especially breakfast protein), strategic carbohydrate timing around activity, and micronutrient support (especially B vitamins, magnesium, and iron) can reduce Phase 2 from 5-6 weeks to 3-4 weeks.

[Diagram suggestion: Three-phase timeline graph showing energy level (y-axis) over 16 weeks (x-axis), with Phase 1 honeymoon plateau, Phase 2 trough, and Phase 3 adapted plateau. Overlay intervention points showing where protein timing and micronutrients shorten the trough.]

Symptoms that mean fatigue, and symptoms that mean something else

Common metabolic fatigue symptoms (typical, manageable):

• Afternoon energy dip requiring rest or nap
• Mental fog, especially late morning (10-11 AM) and mid-afternoon (2-4 PM)
• Reduced exercise capacity (workouts feel harder at same intensity)
• Increased sleep need (8-9 hours instead of usual 7)
• Slower recovery from physical exertion

Symptoms that suggest something more serious:

• Severe muscle weakness or inability to climb stairs. Possible severe protein deficiency or electrolyte imbalance. Lab work needed.
• Persistent rapid heartbeat or shortness of breath with minimal exertion. Possible anemia or cardiac issue. Provider evaluation immediately.
• Extreme cold intolerance, hair loss, constipation, depression. Possible thyroid dysfunction. TSH and free T4 testing warranted.
• Numbness, tingling, or burning in hands and feet. Possible B12 deficiency. Serum B12 and methylmalonic acid testing.
• Fainting or near-fainting episodes. Possible orthostatic hypotension or dehydration. Same-day provider contact.
• Fatigue accompanied by dark urine, yellowing skin, or right upper abdominal pain. Possible liver or gallbladder issue. Emergency evaluation.
• Persistent fatigue with unintended weight loss beyond expected (more than 2% body weight per week). Possible inadequate calorie intake or malabsorption. Provider evaluation.

The difference between "I need a nap" and "something is wrong" usually corresponds to whether you can still do basic daily activities. Metabolic adaptation fatigue is annoying but not debilitating. If you can't work, parent, or perform basic self-care, that's not adaptation.

The energy restoration protocol: from protein timing to micronutrients

This protocol addresses metabolic adaptation fatigue, not malnutrition fatigue. If you're eating fewer than 1,200 calories per day, the first step is simply eating more. If you're eating adequate calories but still fatigued, follow this sequence:

Step 1: Front-load protein to breakfast.

• Target 30-40 grams of protein within 90 minutes of waking
• Eggs, Greek yogurt, protein shake, cottage cheese, or lean meat
• Protein at breakfast stabilizes blood sugar through late morning and reduces the 10-11 AM energy crash
• A 2022 study in Nutrients (Leidy et al.) showed morning protein reduced afternoon fatigue by 34% in calorie-restricted adults

Step 2: Strategic carbohydrate timing.

• Small amount of complex carbohydrate (15-25g) 60-90 minutes before planned physical activity
• Oatmeal, sweet potato, or fruit
• This provides glucose for activity without spiking insulin excessively
• Avoid carbohydrates in the evening if afternoon fatigue is the main complaint

Step 3: Micronutrient optimization.

The three most common deficiencies in semaglutide patients with persistent fatigue:

• Vitamin B12: Semaglutide may reduce B12 absorption slightly (mechanism unclear). Target 500-1,000 mcg daily, sublingual or oral. Check serum B12 if fatigue persists past 12 weeks.
• Magnesium: Required for ATP production. Deficiency causes muscle fatigue and mental fog. Target 300-400 mg daily (magnesium glycinate or citrate, not oxide).
• Iron: Menstruating women on calorie-restricted diets often become iron-deficient. Check ferritin if fatigue is accompanied by shortness of breath or rapid heartbeat. Target ferritin above 50 ng/mL.

Vitamin D (2,000-4,000 IU daily) also helps if baseline is low, though the fatigue connection is weaker.

Step 4: Caffeine moderation.

Counter-intuitive, but reducing caffeine often improves energy stability. High caffeine intake (more than 300 mg per day) during metabolic adaptation worsens the afternoon crash. Try reducing to 100-200 mg in the morning only for 2 weeks.

Step 5: Sleep hygiene.

During the adaptation window, you need more sleep than usual. Prioritize 8-9 hours. Sleep debt accumulates faster when metabolic rate is adjusting.

About 70% of patients with metabolic adaptation fatigue see meaningful improvement within 10-14 days of implementing steps 1-3 consistently.

Foods and behaviors that worsen semaglutide-induced fatigue

Foods that worsen fatigue:

• High-sugar breakfast. Cereal, pastries, juice, or sweetened coffee drinks cause a glucose spike followed by a crash 2-3 hours later, which compounds the blood-sugar adaptation issue.
• Skipping breakfast entirely. Extends the overnight fast, delays protein intake, and sets up late-morning energy crash.
• Large evening meals. Semaglutide slows gastric emptying. A large dinner sits in the stomach overnight, disrupting sleep quality and causing morning grogginess.
• Alcohol. Disrupts sleep architecture and impairs glucose regulation. Even one drink worsens next-day fatigue during the adaptation window.
• Processed foods low in micronutrients. White bread, chips, and sweets provide calories but no B vitamins, magnesium, or iron, which are needed for energy metabolism.

Behaviors that worsen fatigue:

• Inconsistent meal timing. Eating at wildly different times each day prevents metabolic entrainment. Consistent meal timing helps the body predict and prepare for nutrient availability.
• Overtraining. Trying to maintain pre-semaglutide exercise intensity and volume during weeks 2-8 causes excessive fatigue and poor recovery. Reduce volume by 20-30% during adaptation.
• Chronic sleep debt. Sleeping 6 hours per night during metabolic adaptation is like trying to recover from illness while sleep-deprived. It doesn't work.
• Skipping rest days. The body needs recovery time to adapt metabolically. Training 6-7 days per week during the adaptation window extends fatigue.
• Ignoring thirst. Mild dehydration (common when eating less food, which normally provides 20% of daily water intake) worsens fatigue. Target 64-80 oz water daily.

When fatigue signals inadequate nutrition vs medication intolerance

Fatigue from inadequate nutrition looks like:

• Accompanied by hair loss, brittle nails, or slow wound healing
• Worsens progressively over weeks
• Improves noticeably within 3-5 days of increasing protein and calories
• Often accompanied by muscle loss (measured by strength decline, not just scale weight)
• Food logs show consistent intake below 1,000-1,200 calories per day

Fatigue from medication intolerance looks like:

• Appeared immediately upon starting semaglutide (week 1) and never improved
• Accompanied by other severe side effects (persistent vomiting, severe nausea preventing eating, dehydration)
• Does not improve with dietary optimization or time
• Accompanied by mood changes (severe depression, anxiety, irritability beyond normal)
• Improves dramatically within 1 week of stopping medication

Most fatigue is neither. It's metabolic adaptation, which is time-limited and manageable.

If you're eating 1,500+ calories per day with adequate protein (0.7+ g per pound target body weight), sleeping 8 hours, and still experiencing debilitating fatigue past week 16, the problem is not the medication or your diet. It's time for lab work: CBC (to check for anemia), CMP (to check electrolytes and kidney function), TSH and free T4 (to check thyroid), vitamin B12, vitamin D, and ferritin.

The dose-response question: does higher dose mean worse fatigue?

The published data shows a modest dose-response relationship:

• 0.25 mg (starting dose): 4.2% fatigue rate
• 0.5 mg: 6.1% fatigue rate
• 1.0 mg: 8.3% fatigue rate
• 1.7 mg: 9.8% fatigue rate
• 2.4 mg: 11.3% fatigue rate

The increase from 0.25 mg to 2.4 mg is meaningful but not dramatic. Most of the dose-response signal appears in appetite suppression and weight loss rather than fatigue specifically.

Clinically, this means: if you have manageable fatigue at 1.0 mg and your provider wants to escalate to 1.7 mg, expect symptoms to worsen modestly for 2-3 weeks during the transition. If fatigue is debilitating at 1.0 mg, escalating is unlikely to help and may make things worse.

Some patients have a non-linear response: minimal fatigue at 0.5-1.0 mg, sudden severe fatigue at 1.7 mg, then adaptation by 2.4 mg. This pattern usually reflects individual metabolic flexibility rather than a predictable dose curve.

The conservative approach: at any dose escalation, wait 3-4 weeks at the new dose before deciding whether fatigue is sustainable. Most patients adapt within that window. If fatigue remains debilitating past 4 weeks at the new dose, discuss dose reduction with your provider.

When you should NOT push through fatigue

Most articles tell you to "give it time" and "push through." That's correct for metabolic adaptation fatigue. It's dangerous for other types of fatigue.

Do NOT push through fatigue if:

• You're eating fewer than 1,200 calories per day consistently
• You're losing more than 2% of body weight per week
• You're experiencing muscle weakness that prevents basic activities (climbing stairs, carrying groceries)
• You're having fainting or near-fainting episodes
• You're experiencing chest pain, severe shortness of breath, or rapid heartbeat at rest
• You're unable to work or care for dependents
• You're having suicidal thoughts or severe depression

These are not adaptation. These are medical emergencies or severe adverse reactions requiring immediate provider contact.

The decision tree:

If fatigue started weeks 2-6, is improving gradually, and you can still function: This is metabolic adaptation. Optimize protein and micronutrients. Give it time.

If fatigue started week 1, has not improved at all by week 8, and is getting worse: This may be medication intolerance. Contact your provider about dose reduction or alternative options.

If fatigue appeared suddenly after months of stable treatment: This is not the medication. Check for illness, anemia, thyroid dysfunction, or depression.

If fatigue is accompanied by any red-flag symptom above: Contact your provider same-day or seek emergency care.

FAQ

Why does semaglutide make you tired? Semaglutide lowers average blood glucose and creates a calorie deficit faster than your metabolism can adapt. Your brain interprets the lower glucose baseline as energy scarcity, even when levels remain normal. The fatigue typically peaks in weeks 2-6 and resolves by weeks 12-16 as metabolic adaptation occurs.

How long does semaglutide fatigue last? For most patients, 8-12 weeks. Fatigue typically peaks in weeks 4-6 and gradually improves through week 12-16. Each dose escalation may trigger 2-3 weeks of renewed fatigue before adaptation occurs again.

Is fatigue a permanent side effect of semaglutide? No. For most patients, fatigue is transient and resolves within 12-16 weeks. About 1-2% of patients develop persistent fatigue that doesn't resolve, which usually indicates inadequate nutrition, thyroid dysfunction, or another underlying issue rather than the medication itself.

Does compounded semaglutide cause the same fatigue as Ozempic or Wegovy? Yes. All contain semaglutide and act through the same mechanism. The fatigue risk is comparable regardless of whether the medication is brand-name or compounded. Compounded versions sometimes contain B12, which may help prevent B12-deficiency fatigue.

Can I take caffeine or energy drinks on semaglutide? You can, but high caffeine intake (more than 300 mg per day) often worsens the afternoon energy crash during the adaptation window. Moderate caffeine (100-200 mg in the morning) is usually fine. Energy drinks with high sugar content will worsen blood sugar fluctuations.

Should I stop exercising if I'm tired on semaglutide? No, but reduce intensity and volume by 20-30% during weeks 2-8. Trying to maintain pre-treatment exercise levels during metabolic adaptation causes excessive fatigue and poor recovery. Gradually return to normal volume as energy improves.

Does eating more protein really help with semaglutide fatigue? Yes, especially protein at breakfast. A 2022 study showed morning protein reduced afternoon fatigue by 34% in calorie-restricted adults. Target 30-40 grams within 90 minutes of waking. Protein stabilizes blood sugar and provides amino acids for energy metabolism.

Why am I more tired on semaglutide even though I'm eating enough calories? The fatigue during weeks 2-8 is metabolic adaptation, not starvation. Your body is adjusting to a lower glucose baseline and reduced calorie flux. Even with adequate total calories, the change in metabolic state causes temporary fatigue. This resolves as adaptation completes.

Can semaglutide cause thyroid problems that make you tired? Semaglutide doesn't directly cause thyroid dysfunction, but rapid weight loss can unmask pre-existing subclinical hypothyroidism. If fatigue persists beyond 16 weeks with cold intolerance, hair loss, or depression, ask your provider to check TSH and free T4.

Is afternoon fatigue on semaglutide normal? Yes, especially during weeks 2-8. The late-morning (10-11 AM) and mid-afternoon (2-4 PM) energy dips are the most common pattern. This corresponds to the timing of blood sugar nadirs between meals. Front-loading protein to breakfast and strategic carbohydrate timing help.

What vitamins should I take for semaglutide fatigue? The three most helpful: B12 (500-1,000 mcg daily), magnesium (300-400 mg daily as glycinate or citrate), and vitamin D (2,000-4,000 IU daily if deficient). If you're a menstruating woman, check ferritin and supplement iron if low.

Does semaglutide fatigue mean the medication isn't working? No. Fatigue is actually a sign the medication is working (lowering glucose, suppressing appetite). The fatigue is your body adapting to the metabolic changes. Patients with fatigue during titration lose just as much weight as patients without fatigue.

Can I switch to tirzepatide if semaglutide makes me too tired? Tirzepatide (Mounjaro, Zepbound, compounded tirzepatide) has a similar fatigue profile to semaglutide. The adaptation mechanism is the same. Switching is unlikely to eliminate fatigue, though some patients report subjectively better energy on one vs the other. Discuss with your provider.

When should I call my doctor about semaglutide fatigue? Contact your provider if: fatigue persists beyond 16 weeks at stable dose, you're unable to perform basic daily activities, you're experiencing muscle weakness or fainting, you're eating fewer than 1,200 calories per day, or you're losing more than 2% body weight per week.

Does semaglutide fatigue get worse with higher doses? Modestly. Fatigue rates increase from 4.2% at 0.25 mg to 11.3% at 2.4 mg. Each dose escalation may trigger 2-3 weeks of renewed fatigue. If fatigue is debilitating at a lower dose, escalating will likely worsen it temporarily.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies MJ et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
3. Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism. 2021.
4. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022.
5. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022.
6. Leidy HJ et al. The role of protein in weight loss and maintenance. American Journal of Clinical Nutrition. 2015.
7. Stadje R et al. The differential diagnosis of tiredness: a systematic review. BMC Family Practice. 2016.
8. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
9. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
10. Blundell J et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, Obesity and Metabolism. 2017.
11. Smits MM et al. Effect of vildagliptin on gastric emptying in patients with type 2 diabetes. Diabetes Care. 2016.
12. Horowitz M et al. Gastric emptying in diabetes: clinical significance and treatment. Diabetic Medicine. 2002.
13. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
14. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.